/BSYI

BSYI Stock - BioSyntech, Inc.

Q: What is the analyst price target for BSYI?

Analyst price target information is not currently available for BSYI.

Q: What is BSYI's market cap?

Market capitalization information is not currently available for BSYI.

Healthcare|Biotechnology|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Sep 24

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BSYI

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2004

FY2005

FY2006

FY2007

FY2008

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.15

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2008	FY2007	FY2006	FY2005	FY2004
Revenue	$40,766	$273,925	$243,475	$61,505	$178,001
Gross Profit	$24,795	$172,044	$153,620	$40,101	$98,164
Gross Margin	60.8%	62.8%	63.1%	65.2%	55.1%
Operating Income	$-11,029,752	$-9,198,514	$-7,295,100	$-6,365,163	$-4,779,755
Net Income	$-12,938,767	$-9,269,131	$-8,113,553	$-6,855,050	$-5,142,335
Net Margin	-31739.1%	-3383.8%	-3332.4%	-11145.5%	-2888.9%
EPS	$-0.13	$-0.10	$-0.09	$-0.17	$-0.14

Company Overview

BioSyntech, Inc. develops biotherapeutic thermogels for tissue repair and therapeutic delivery. Its lead products in development include BST-CarGel, a biodegradable gel for cartilage repair; BST-InPod for heel pain relief; BST-DermOn for chronic wound healing; BST-Ossifil for bone filling; BST-Ossifix for bone structural support; and BST-Disc for intervertebral disc restoration. The company's products also comprise BST-Gel-based injectable products that deliver biotherapeutics to their targeted site of action; Arthro-BST, an arthroscopic device used for the non-destructive evaluation of cartilage degradation and/or repair; and Mach-1, a micromechanical testing system for evaluating the mechanical properties of tissues and materials. In addition, it manufactures ultra pure chitosans under the Ultrasan name; and offers manufacturing and analytical services. The company was incorporated in 1994 and is based in Laval, Canada. On May 12, 2010, Biosyntech Inc. filed for administration under the Bankruptcy and Insolvency Act. Biosyntech Inc. is in reorganization.